Association between circulating inflammatory proteins and benign prostatic disease: a Mendelian randomization study.
Benign prostatic disease
Causal effects
Circulating inflammatory proteins
Mendelian randomization
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
10 10 2024
10 10 2024
Historique:
received:
21
06
2024
accepted:
30
09
2024
medline:
11
10
2024
pubmed:
11
10
2024
entrez:
10
10
2024
Statut:
epublish
Résumé
Previous research has suggested that circulating inflammatory proteins are associated with benign prostatic disease (BPD). This Mendelian randomization (MR) study was conducted to further investigate the causal relationship between 91 inflammatory proteins and BPD. Genome-wide association study (GWAS) summarized data of benign prostatic hyperplasia (BPH) and prostatitis were obtained from the FinnGen Biobank. The latest study offered the GWAS data on 91 proteins related to inflammation. We performed a bidirectional MR to investigate the causal association between inflammatory proteins and BPD. The outcomes of the IVW method indicated that decreased levels of circulating interleukin-17 C (IL-17 C) (OR = 0.92, 95%CI = 0.85-0.99, p-value = 0.0344) were suggestively associated with a higher risk of BPH and elevated levels of interleukin-10 receptor subunit alpha (IL-10RA) (OR = 1.24, 95%CI = 1.05-1.47, p-value = 0.0132) and urokinase-type plasminogen activator (uPA) (OR = 1.13, 95%CI = 1.00-1.28, p-value = 0.0421) were suggestively related to a higher risk of prostatitis. Furthermore, reverse MR revealed that BPH may promote the expression of circulating factors, including natural killer cell receptor 2B4 (CD244) (OR = 1.07, 95%CI = 1.01-1.13, p-value = 0.0192), T-cell surface glycoprotein CD6 isoform (CD6) (OR = 1.07, 95%CI = 1.01-1.13, p-value = 0.0192), and leukemia inhibitory factor receptor (LIF-R) (OR = 1.07, 95%CI = 1.01-1.15, p-value = 0.0163). Moreover, the results of sensitivity analyses indicate that heterogeneity and horizontal pleiotropy are unlikely to distort the findings. The results of this study indicate a potential association between circulating inflammatory proteins and BPD, which may become new diagnostic indicators or drug targets for clinical application in the prevention and treatment of BPD. However, further investigation is required.
Identifiants
pubmed: 39390078
doi: 10.1038/s41598-024-74737-2
pii: 10.1038/s41598-024-74737-2
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
23667Subventions
Organisme : Jilin Provincial Department of Finance
ID : JLSWSRCZX2020-058
Organisme : WU JIEPING Medical Foundation
ID : 320.6750.2020-06-37
Organisme : Department of Science and Technology of Jilin Province
ID : 20210401154YY
Informations de copyright
© 2024. The Author(s).
Références
Launer, B. M., McVary, K. T., Ricke, W. A. & Lloyd, G. L. The rising worldwide impact of benign prostatic hyperplasia. BJU Int. 127, 722–728 (2021).
doi: 10.1111/bju.15286
pubmed: 33124118
Khan, F. U. et al. Comprehensive overview of prostatitis. Biomed. Pharmacother. 94, 1064–1076 (2017).
doi: 10.1016/j.biopha.2017.08.016
pubmed: 28813783
Schaeffer, A. J. Epidemiology and evaluation of chronic pelvic pain syndrome in men. Int. J. Antimicrob. Agents 31(Suppl 1), S108–S111 (2008).
doi: 10.1016/j.ijantimicag.2007.08.027
pubmed: 18164597
Murphy, A. B., Macejko, A., Taylor, A. & Nadler, R. B. Chronic prostatitis: management strategies. Drugs 69, 71–84 (2009).
doi: 10.2165/00003495-200969010-00005
pubmed: 19192937
Jang, T. L. & Schaeffer, A. J. The role of cytokines in prostatitis. World J. Urol. 21, 95–99 (2003).
doi: 10.1007/s00345-003-0335-2
pubmed: 12783173
Chen, L. et al. Immunological alterations in patients with chronic prostatitis/chronic pelvic pain syndrome and experimental autoimmune prostatitis model: a systematic review and meta-analysis. Cytokine 141, 155440 (2021).
doi: 10.1016/j.cyto.2021.155440
pubmed: 33550164
Tsunemori, H. & Sugimoto, M. Effects of inflammatory prostatitis on the development and progression of benign prostatic hyperplasia: a literature review. Int. J. Urol. 28, 1086–1092 (2021).
doi: 10.1111/iju.14644
pubmed: 34342061
Lloyd, G. L., Marks, J. M. & Ricke, W. A. Benign prostatic hyperplasia and lower urinary tract symptoms: what is the role and significance of inflammation? Curr. Urol. Rep. 20, 54 (2019).
doi: 10.1007/s11934-019-0917-1
pubmed: 31377881
pmcid: 7339114
Swerdlow, D. I. et al. Selecting instruments for Mendelian randomization in the wake of genome-wide association studies. Int. J. Epidemiol. 45, 1600–1616 (2016).
doi: 10.1093/ije/dyw088
pubmed: 27342221
pmcid: 5100611
Sekula, P., Del Greco, M. F., Pattaro, C. & Köttgen, A. Mendelian randomization as an approach to assess causality using observational data. J. Am. Soc. Nephrol. 27, 3253–3265 (2016).
doi: 10.1681/ASN.2016010098
pubmed: 27486138
pmcid: 5084898
Kurki, M. I. et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature 613, 508–518 (2023).
doi: 10.1038/s41586-022-05473-8
pubmed: 36653562
pmcid: 9849126
Zhao, J. H. et al. Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets. Nat. Immunol. 24, 1540–1551 (2023).
doi: 10.1038/s41590-023-01588-w
pubmed: 37563310
pmcid: 10457199
Pierce, B. L., Ahsan, H. & Vanderweele, T. J. Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants. Int. J. Epidemiol. 40, 740–752 (2011).
doi: 10.1093/ije/dyq151
pubmed: 20813862
Verbanck, M., Chen, C. Y., Neale, B. & Do, R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat. Genet. 50, 693–698 (2018).
doi: 10.1038/s41588-018-0099-7
pubmed: 29686387
pmcid: 6083837
Burgess, S., Scott, R. A., Timpson, N. J., Davey Smith, G. & Thompson, S. G. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. Eur. J. Epidemiol. 30, 543–552 (2015).
doi: 10.1007/s10654-015-0011-z
pubmed: 25773750
pmcid: 4516908
Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int. J. Epidemiol. 44, 512–525 (2015).
doi: 10.1093/ije/dyv080
pubmed: 26050253
pmcid: 4469799
Bowden, J., Davey Smith, G., Haycock, P. C. & Burgess, S. Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet. Epidemiol. 40, 304–314 (2016).
doi: 10.1002/gepi.21965
pubmed: 27061298
pmcid: 4849733
Hartwig, F. P., Davey Smith, G. & Bowden, J. Robust inference in summary data mendelian randomization via the zero modal pleiotropy assumption. Int. J. Epidemiol. 46, 1985–1998 (2017).
doi: 10.1093/ije/dyx102
pubmed: 29040600
pmcid: 5837715
Shen, C. et al. Preliminary study of the effect of gut microbiota on the development of prostatitis. BMC Med. Genomics 17, 35 (2024).
doi: 10.1186/s12920-024-01812-y
pubmed: 38273299
pmcid: 10809527
Burgess, S., Butterworth, A. & Thompson, S. G. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet. Epidemiol. 37, 658–665 (2013).
doi: 10.1002/gepi.21758
pubmed: 24114802
pmcid: 4377079
Kramer, G., Mitteregger, D. & Marberger, M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur. Urol. 51, 1202–1216 (2007).
doi: 10.1016/j.eururo.2006.12.011
pubmed: 17182170
Kramer, G. et al. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate. 52, 43–58 (2002).
doi: 10.1002/pros.10084
pubmed: 11992619
Steiner, G. E. et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab. Invest. 83, 1131–1146 (2003).
doi: 10.1097/01.LAB.0000081388.40145.65
pubmed: 12920242
Pontari, M. A. & Ruggieri, M. R. Mechanisms in prostatitis/chronic pelvic pain syndrome. J. Urol. 179, S61–S67 (2008).
doi: 10.1016/j.juro.2008.03.139
pubmed: 18405756
Zhao, Q. et al. Lycopene attenuates chronic prostatitis/chronic pelvic pain syndrome by inhibiting oxidative stress and inflammation via the interaction of NF-κB, MAPKs, and Nrf2 signaling pathways in rats. Andrology 8, 747–755 (2020).
doi: 10.1111/andr.12747
pubmed: 31880092
pmcid: 7317562
Yang, F. et al. New therapy with XLQ(
doi: 10.1002/jcp.28380
pubmed: 30790289
Zang, L. et al. Qianliexin capsule exerts anti-inflammatory activity in chronic non-bacterial prostatitis and benign prostatic hyperplasia via NF-κB and inflammasome. J. Cell. Mol. Med. 25, 5753–5768 (2021).
doi: 10.1111/jcmm.16599
pubmed: 33982874
pmcid: 8184730
Zhang, F. et al. IL-17 C neutralization protects the kidney against acute injury and chronic injury. EBioMedicine 92, 104607 (2023).
doi: 10.1016/j.ebiom.2023.104607
pubmed: 37263138
pmcid: 10277925
Steiner, G. E. et al. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 56, 171–182 (2003).
doi: 10.1002/pros.10238
pubmed: 12772186
Arivazhagan, J., Nandeesha, H., Dorairajan, L. N. & Sreenivasulu, K. Association of elevated interleukin-17 and angiopoietin-2 with prostate size in benign prostatic hyperplasia. Aging Male 20, 115–118 (2017).
doi: 10.1080/13685538.2017.1284778
pubmed: 28590830
Liu, Y. et al. Expression of IL-17A, E, and F and their receptors in human prostatic cancer: comparison with benign prostatic hyperplasia. Prostate 75, 1844–1856 (2015).
doi: 10.1002/pros.23058
pubmed: 26356122
Moore, K. W., de Waal Malefyt, R., Coffman, R. L. & O’Garra, A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19, 683–765 (2001).
doi: 10.1146/annurev.immunol.19.1.683
pubmed: 11244051
Aschenbrenner, D. et al. Pathogenic Interleukin-10 receptor alpha variants in humans—balancing natural selection and clinical implications. J. Clin. Immunol. 43, 495–511 (2023).
doi: 10.1007/s10875-022-01366-7
pubmed: 36370291
Miller, L. J. et al. Interleukin-10 levels in seminal plasma: implications for chronic prostatitis-chronic pelvic pain syndrome. J. Urol. 167, 753–756 (2002).
doi: 10.1016/S0022-5347(01)69139-0
pubmed: 11792966
He, L., Wang, Y., Long, Z. & Jiang, C. Clinical significance of IL-2, IL-10, and TNF-alpha in prostatic secretion of patients with chronic prostatitis. Urology 75, 654–657 (2010).
doi: 10.1016/j.urology.2009.09.061
pubmed: 19963254